uniQure NV Stock Forum

$uniQure NV (QURE.US)$ uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
4 MINUTES AGO, 7:05 AM EST
VIA GLOBENEWSWIRE

$CuriosityStream (CURI.US)$
I went with the wrong Curi! lol, both are good LT though
$uniQure NV (QURE.US)$

$uniQure NV (QURE.US)$ $Apogee Enterprises (APOG.US)$ $Capricor Therapeutics (CAPR.US)$ $noco-noco (NCNC.US)$ $UP Fintech (TIGR.US)$ $JBDI Holdings (JBDI.US)$ $Snail (SNAL.US)$ $Cue Biopharma (CUE.US)$ $Entero Therapeutics (ENTO.US)$ $Power REIT (PW.US)$ $Ford Motor (F.US)$ $Beneficient (BENF.US)$ $Phoenix Motor (PEV.US)$ $Chanson International (CHSN.US)$
📊⚡️📊

$uniQure NV (QURE.US)$
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) announced that the U.S. FDA has granted Orphan Drug Designation to AMT-191, their investigational gene therapy for Fabry disease. This follows the dosing of the first patient in a U.S. multi-center, open-label Phase I/IIa trial in August 2024. AMT-191 is a one-time intravenously administered AAV5-based gene therapy targeting the liver to produce G...

$uniQure NV (QURE.US)$
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure N.V. (NASDAQ: QURE) has initiated dosing in a Phase I/IIa clinical trial of AMT-191 for Fabry diseasetreatment. The multi-center, open-label trial in the US will assess safety, tolerability, and early efficacy signs in two dose-escalating cohorts. AMT-191 is an AAV5-based gene therapy delivering a galactosidase alpha (GLA) transgene to the live...

$uniQure NV (QURE.US)$ ooopsy

$uniQure NV (QURE.US)$ short insiders unloading

$uniQure NV (QURE.US)$ back to square

$uniQure NV (QURE.US)$ zero resistance.. wtf!